The inappropriate use of antipsychotic drugs in nursing homes has been a long-standing issue for the Office of Inspector General (OIG). Recent findings reinforce just how critical proper oversight and clinical decision-making are in protecting vulnerable residents.
In a review of forty focused nursing home inspections completed by the Centers for Medicare & Medicaid Services (CMS), the OIG identified several troubling patterns.
Key Findings from the OIG Review
The report revealed residents with dementia were frequently administered antipsychotic medications to control their behavioral symptoms —despite Food & Drug Administration (FDA) warnings of an increased risk of death in this population.
Beyond medication use itself, the OIG found systemic breakdowns in safeguards designed to protect residents:
- Steps were not taken to protect the residents prescribed these drugs.
- Medical Directors failed to prevent the inappropriate use of antipsychotic drugs.
- Pharmacists failed to identify potential medical concerns and did not recommend dose reductions.
- Nursing homes had inadequate policies and procedures that undermined safeguards to protect residents.
OIG Recommendations to CMS
To address these concerns, the OIG recommends that CMS take several actions:
- Develop additional resources for nursing homes to support appropriate dementia care
- Increase transparency around antipsychotic medication use
- Ensure Medical Directors and Pharmacists are actively fulfilling their roles in oversight
- Provide guidance to help facilities strengthen policies and procedures related to antipsychotic use
These recommendations signal continued regulatory focus—and increased expectations—for providers.
What Providers Should Be Doing Now
Nursing homes need to have a clinical rationale for giving an antipsychotic medication. The rationale must be based on an assessment of the resident’s clinical condition. Ensure documentation of non-drug interventions attempted prior to initiating a medication. Decisions about interventions should be guided by key steps, such as evaluating and understanding the origin of the behavior, addressing any underlying environmental factors, and ruling out underlying physical illness or needs. Ensure the Medical Director and Pharmacist understand their roles in preventing the inappropriate use of these drugs. Develop policies and procedures that are written to protect residents. Review documentation for monitoring side effects, as well as the resident’s behaviors to assess the effectiveness of medications. Ensure documentation supports periodic assessment of the continued need of the dose and that dose reductions have been attempted or are clinically contraindicated. Lastly, if the diagnosis of schizophrenia is used be sure that it is a well-documented history of schizophrenia and not used only to justify the use of antipsychotic medications.
How LW Consulting, Inc. Can Help
The OIG’s findings make one thing clear: inappropriate antipsychotic use is not just a clinical issue—it’s a compliance risk with serious implications.
For nursing home providers, the path forward requires a combination of strong clinical practices, clear documentation, and accountable leadership. Organizations that take a proactive approach now will be better positioned to withstand regulatory scrutiny—and, most importantly, provide safer, more appropriate care for their residents.
If your organization needs support in this area, we welcome the opportunity to connect. Our team brings an experienced, objective perspective to help you navigate complex regulatory requirements and enhance resident safety.
LW Consulting, Inc. (LWCI) offers a comprehensive range of services that can assist your organization in maintaining compliance, identifying trends, providing education and training, or conducting documentation and coding audits. For more information, contact LWCI to connect with one of our experts!
